Phenotypical Characterization of Peanut Allergic Children
1 other identifier
observational
317
0 countries
N/A
Brief Summary
Peanut allergy (PA) has been well studied and its prevalence was estimated up to 1.3% in Europe. Tree nut (TN) allergy and PA are clinically similar and often coexist, TN allergy prevalence ranged from 0.05 to 4.9 %. TN allergy is longlasting and nearly all TN have been associated with fatal allergic reactions . Other legumes or TN also contain seed storage protein orthologs of the globulins (Ara h1, Ara h 3) and 2S albumins (Ara h 2) of peanut, susceptible to provoke allergic reactions, but cross-reactivity to TN and other legumes in PA patients could also appear through primarily sensitization. These possible IgE-binding cross-reactions bring to recommend the avoidance of TN and other legumes which have never been eaten in PA children. In this context, diagnosis work-up of relevant cross-allergy versus asymptomatic cross-sensitization will impact directly children's health-related quality of life (HRQL). When physicians suspect food allergy, many parameters have to be considered, such as clinical background, clinical history, type of symptoms related to the suspected food and cross-allergy to other foods. Then, to objectively confirm a food allergy and to assess its severity (related to the threshold reactive dose and symptoms), an oral food challenge (OFC) is demanded, and double-blind placebo-controlled food challenge (DBPCFC) is considered as "the gold standard". Although OFC are more and more available in the diagnosis of PA, the assessment of cross-allergy to every single allergenic TN and legumes requires full allergy work-up and often many years of follow-up. Few studies investigated cross-allergy to TN and other legume, with rates of cross-allergy to TN between 28% and 50%. However, targeting patients with severe or cross-allergic phenotypes would greatly assist the allergist in management and follow-up of PA patients (i.e., planning OFC to cross-reactive food). Our main objective is to identify different disease phenotypes of PA children with cluster analysis. This statistical approach has never been performed to identify cross-allergic phenotypes. We also will describe cross-allergy in PA and will identify possible risk factors for cross-allergy to TN and other legumes in PA children.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 8, 2016
CompletedFirst Posted
Study publicly available on registry
November 11, 2016
CompletedNovember 11, 2016
November 1, 2016
8 months
November 8, 2016
November 10, 2016
Conditions
Outcome Measures
Primary Outcomes (4)
Double-blind placebo-controlled food challenge Test for determination of type of allergic reaction
After the test (DBPCFC) the type of allergic reaction will be registered: asthma and allergic rhinitis (AR)
at inclusion
Double-blind placebo-controlled food challenge Test for determination of threshold reactive dose
at inclusion
Measure of specific IgEs for the peanut component Ara h 1, Ara h 2, Ara h 3
at inclusion
Oral food challenge test for diagnosis of tree nuts and/or other legumes allergies
through the study completion
Study Arms (1)
Peanut allergic children
Interventions
Eligibility Criteria
Children with peanut allergy who had a complete evaluation about cross-allergy to Tree Nuts and other legumes
You may qualify if:
- Child evaluated at the allergy Unit of Saint Vincent Hospital of Lille (France) from March 2004 to May 2016
- Peanut allergy proven with a double-blind placebo-controlled food challenge
You may not qualify if:
- Patients who had incomplete evaluation for major peanut component at the time of their double-blind placebo-controlled food challenge to peanut.
- All patients refusing Oral Food Challenge.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mathias Cousin, MD
GHICL
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 8, 2016
First Posted
November 11, 2016
Study Start
January 1, 2016
Primary Completion
September 1, 2016
Study Completion
September 1, 2016
Last Updated
November 11, 2016
Record last verified: 2016-11
Data Sharing
- IPD Sharing
- Will not share